business
Banking giant massively resets Jazz Pharma stock price target
Key takeaways
- Banking giant massively resets Jazz Pharma stock price target Peace Longe Sun, May 24, 2026 at 1:03 AM GMT+7 5 min read JAZZ Changes in Wall Street price targets usually arrive in small increments.
- UBS skipped that script with Jazz Pharmaceuticals (JAZZ).
- On May 19, UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals two notches, from neutral straight to buy, and lifted his price target to $307 from $188.
Banking giant massively resets Jazz Pharma stock price target Peace Longe Sun, May 24, 2026 at 1:03 AM GMT+7 5 min read JAZZ Changes in Wall Street price targets usually arrive in small increments. A few dollars up, a few dollars down, and sometimes a rating left untouched.
UBS skipped that script with Jazz Pharmaceuticals (JAZZ).
On May 19, UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals two notches, from neutral straight to buy, and lifted his price target to $307 from $188. That is a 63% jump in one move, and it sits well above the prior analyst consensus of roughly $242.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop